Laboratory implementation of human papillomavirus testing

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 8, 2003, Pages 984-990

  Bolick, David R ^a  

^a AmeriPath Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA HYBRID;

ASSAY; CANCER SCREENING; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DISPOSABLE EQUIPMENT; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; LABORATORY TEST; METHODOLOGY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PROFIT; REIMBURSEMENT; RNA PROBE; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS DIAGNOSIS; WART VIRUS; DIAGNOSTIC PROCEDURE; ECONOMICS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; LABORATORY; PAPILLOMA VIRUS; PATHOLOGY; REVIEW; STANDARD; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

FEMALE; HUMANS; LABORATORIES; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0041672578     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
2. Manos MM, Kinney WK, Hurley LB. Identifying women with cervical neoplasia, using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
3. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287: 2382-2390.
4. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
5. Digene HC2 [package insert]. Gaithersburg, Md: Digene Corp; 2002.
6. Bolick DB, Coates F. Comparison of the detection rate of human papilloma virus in AutoCyte™ PREP and ThinPrep Pap test specimens. Acta Cytol. 2001;45: 821.
7. Bolick DB, Coates F. Frequency of human papilloma virus specimens with atypical glandular cells of undetermined significance and adenocarcinoma in situ. Acta Cytol. 2001;45:808.
8. Qureshi MN, Mansukhani M, Layfield L, McGleenon RC, Ringer P, Rudelli RD. Comparison of HC II®, Inform® HPV and PCR methodologies in diagnosing high risk and low risk types of HPV: evaluation of predictive value and cross-reactivity. Acta Cytol. 2002;46:927.
9. Biscotti CV, Layfield L, Qureshi MN, Tubbs RR. Interobserver agreement with the Inform LBP HPV® test. Acta Cytol. 2002;46:927.
10. Zehbe I, Hacker GW, Su H, Hauser-Kronberger C, Hainfield JF, Tubbs R. Sensitive in situ hybridization with catalyzed reporter deposition, streptavidin-Nanogold, and silver acetate autometallography: detection of single-copy human papillomavirus. Am J Pathol. 1997;150:1553-1561.
11. Zehbe I, Rylander E, Strand S, Wilander E. Use of Probemix and Omni-Probe biotinylated cDNA probes for detecting HPV infection in biopsy specimens from the genital tract. J Clin Pathol. 1993;46:437-440.
12. Medicare Fee Schedule. Baltimore, Md: Centers for Medicare & Medicaid Services; 2002.
13. Expanded PCR Diagnostic Service Agreement. Indianapolis, Ind: Hoffmann La Roche; 2002.
14. SCF Advisors. SCF Advisors Pathology Industry Research Report. San Francisco, Calif: SCF Advisors; 2002.
15. Goldwasser R, Ulrich B. UBS Warburg's Life Sciences Global Equity Research Group [industry research report]. New York, NY: UBS Warburg LLC; May 15, 2002.